Novo's oral GLP-1 analog meets in first Phase IIIa for Type II diabetes

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said oral semaglutide met the primary endpoint in the Phase IIIa PIONEER 1 trial to treat Type II diabetes.

Read the full 248 word article

User Sign In